IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer - Yahoo Finance

IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer  Yahoo Finance

Trial showed statistically-significant and clinically meaningful benefit in patients with the most aggressive type of lung cancer.



Comments

Popular posts from this blog

His Apple Watch warned of an irregular heart rate. Turns out he was having a heart attack | Globalnews.ca - Global News Toronto

“Opioids in America, Part 3: The other side of the crisis - Greeley Tribune” plus 1 more

“A Runner Suddenly Developed Asthma. It Was Stranger Than It Seemed. - The New York Times” plus 1 more